- Messages
- 22,171
- Reaction score
- 2,797
- # of dives
- 5000 - ∞
Why this piece from the New Scientist has not had more coverage is beyond me.
Welcome to ScubaBoard, the world's largest scuba diving community. Registration is not required to read the forums, but we encourage you to join. Joining has its benefits and enables you to participate in the discussions.
Benefits of registering include
Probably because of the prevailing "Panem et circem" mentality of today. But excellent news, thanks for posting!Thalassamania:Why this piece from the New Scientist has not had more coverage is beyond me.
Thalassamania:Why this piece from the New Scientist has not had more coverage is beyond me.
The drug, dichloroacetate (DCA), has already been used for years to treat rare metabolic disorders and so is known to be relatively safe.
DCA can cause pain, numbness and gait disturbances in some patients, but this may be a price worth paying if it turns out to be effective against all cancers. The next step is to run clinical trials of DCA in people with cancer. These may have to be funded by charities, universities and governments: pharmaceutical companies are unlikely to pay because they can’t make money on unpatented medicines. The pay-off is that if DCA does work, it will be easy to manufacture and dirt cheap.
Thalassamania:But it's already FDA approved for treating various metabolic disorders and using for cancer treatment is just an "off label" use. That (and the fact that it's in the public domain) is what makes this interesting. In theory, if you so chose, you could get a script and use it this afternoon.
Thalassamania:In theory, if you so chose, you could get a script and use it this afternoon.
Thalassamania:In theory, if you so chose, you could get a script and use it this afternoon.
The drug, dichloroacetate (DCA), has already been used for years to treat rare metabolic disorders and so is known to be relatively safe.
Results of 2006 study published by the American Academy of Neurology: During the treatment period, all patients randomized to DCA were taken off study medication because of peripheral neuropathy, and trial was terminated early because of peripheral nerve toxicity. Conclusion: DCA is associated with peripheral nerve toxicity and the findings show that DCA-associated neuropathy overshadows the assessment of any potential benefit.
Thalassamania:Someone, it appears, (and I don't mean RJP, who is going through the trouble to look up more data for us ... thanks) is not giving us the straight story!